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Objective To investigate the natural susceptibility to 69 antimicrobial agents of 107
Enterobacter strains comprising E. amnigenus (n¼ 18), E. cancerogenus (n¼ 26), E. gergoviae
(n¼ 28) and E. sakazakii (n¼ 35).
Methods Minimal inhibitory concentrations (MICs) were determined with a microdilu-
tion procedure in Isosensitest broth and cation-adjusted Mueller–Hinton broth.
Results All the species were naturally sensitive or intermediate to tetracyclines, amino-
glycosides, numerous b-lactams (acylureidopenicillins, ticarcillin, ampicillin/sulbactam,
several cephalosporins, carbapenems, aztreonam), quinolones, antifolates, chloramphe-
nicol and nitrofurantoin. Natural resistance was found to penicillin G, oxacillin, several
macrolides, lincosamides, streptogramins, glycopeptides, rifampicin and fusidic acid.
Species-related differences in natural susceptibility were found to some b-lactams,
azithromycin and fosfomycin. Whereas E. gergoviae was the most susceptible species
to azithromycin, E. cancerogenus was most susceptible to fosfomycin and was the only
species showing natural resistance to amoxicillin, amoxicillin/clavulanic acid, cefaclor,
cefazoline, loracarbef and cefoxitin. There were only minor medium-dependent differ-
ences in susceptibility to most antibiotics.
Conclusions The present study establishes a database concerning the natural suscept-
ibility of recently established Enterobacter species to a wide range of antibiotics, which can
be applied for the validation of routine susceptibility test results. b-Lactam susceptibility
patterns indicate the expression of species-specific b-lactamases expressed at high or low
levels in all the species except E. sakazakii.
Keywords Natural antibiotic susceptibility, Enterobacter amnigenus, Enterobacter cancero-
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resistant, b-lactamase
Accepted 15 November 2001
Clin Microbiol Infect 2002; 8: 564–578
I N T R O D U C T I O N
Enterobacter species are common causes of
nosocomial infections in humans. Apart from
E. hormaechei, E. asburiae and E. aerogenes, which
represent the most frequently encountered
Enterobacter species in clinical specimens, there
are several further Enterobacter taxa associated
with human disease. The most common is
E. sakazakii, a yellow-pigmented and biochem-
ically heterogeneous species with an unusual
thermotolerance [1,2]. Enterobacter sakazakii, first
described in 1980 [3], is an important agent of
life-threatening neonatal sepsis and meningitis,
with mortality rates of 40–80% [4,5]. In some
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cases these diseases are complicated by the deve-
lopment of brain abscesses and other secondary
disorders [6]. Enterobacter sakazakii was also shown
to cause an outbreak of severe necrotizing enter-
ocolitis in a neonatal intensive care unit in Belgium
[7]. Although the guts of insects were shown to
contain the species [8] and dried infant formula
milk has been implicated in both outbreaks and
sporadic cases of E. sakazakii meningitis [4], its
natural habitat remains obscure [3,4].
In 1981, Izard et al. described Enterobacter strains
previously called Enterobacter H3 [9], and called
them E. amnigenus [10]. These bacteria have been
isolated from water and from several clinical
specimens, e.g. respiratory tract, wound, blood
and feces [11], and were shown to cause sepsis
and other infections in man [12–14]. Strains of
E. cancerogenus have been isolated predominantly
from human blood and spinal fluid [15] and were
found to be etiological agents of wound
and urinary tract infections, sepsis and osteo-
myelitis [16–21]. Enterobacter taylorae, described
in 1985 by Farmer et al. [15], was shown to be a
junior synonym of E. cancerogenus [22]. A further,
widely distributed Enterobacter species is E. gergo-
viae. It has been isolated from environmental
samples and clinical specimens and is likely to
cause sepsis and urinary tract infections [5,23].
Although there is some information on antimi-
crobial susceptibility patterns of recently estab-
lished Enterobacter species, in most cases only a
small number of strains/species and/or a few
antibiotics have been examined. Data on natural
sensitivities or resistances are exceptional.
The aim of the present study was to establish a
database concerning the natural susceptibility to a
wide range of antibiotics of strains of E. amnigenus,
E. cancerogenus, E. gergoviae and E. sakazakii, exam-
ining isolates from different sources and areas. In
particular, it was investigated whether there are
species-related differences in natural susceptibil-
ity. The data from 107 strains tested with 69 anti-
biotics can be valuable for the validation of routine
susceptibility test results.
M A T E R I A L S A N D M E T H O D S
Bacterial strains
A total of 107 Enterobacter strains was examined.
Most strains were taken from clinical specimens,
but environmental strains were also included.
Data on the strains studied are summarized in
Table 1. Enterobacter amnigenus ATCC 33072T, E.
cancerogenus ATCC 33241T, E. gergoviae ATCC
Table 1 Enterobacter strains tested
Origin
Strain (additional designation) Material Country Source
E. amnigenus (n¼ 18)
20.01 (ATCC 33072T, LMG 2784) Soil France H. Backes, Germanya
20.02 (CUETM 78-97, LMG 3006) Water France
20.03 (ATCC 33072) Unknown USA
20.04 (ATCC 33731, LMG 2998) Unknown France
20.05 (Eam1) Human clinical specimen Switzerland A. v. Graevenitz, Switzerlandb
20.06 (Eam2) Human clinical specimen Switzerland
20.07 (Eam3) Human clinical specimen Switzerland
20.08 (WG-01) Human clinical specimen Germany G. Stempfel, Germanyc
20.09 (WG-02) Human clinical specimen Germany
20.10 (WG-03) Human clinical specimen Germany
20.11 (WG-04) Human clinical specimen Germany
20.12 (WG-05) Human clinical specimen Germany
20.13 (CUETM 77-137, LMG 2999) Water France J. Swings, Belgiumd
20.14 (CUETM 78-65, LMG 3000) Water France
20.15 (CUETM 78-73, LMG 3001) Water France
20.16 (CUETM 78-77, LMG 3002) Water France
20.17 (CUETM 78-86, LMG 3004) Water France
20.18 (CUETM 78-100, LMG 3007) Water France
E. cancerogenus (n¼ 26)
16.01 (154/86) Human clinical specimen Unknown H. Backes, Germanya
16.02 (152/86) Human clinical specimen Unknown
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Table 1 continued
Origin
Strain (additional designation) Material Country Source
16.03 (153/86) Human clinical specimen Unknown
16.04 (155/86) Human clinical specimen Unknown
16.05 (151/86) Human clinical specimen Unknown
16.06 (CDC 4914.84) Human clinical specimen USA
16.07 (CDC 2126.81) Human clinical specimen USA
16.08 (CDC 4254.85) Human clinical specimen USA
16.09 (15/1) Human clinical specimen Germany Own culture collection
16.10 (ATCC 33241T, LMG 2693) Populus canadensis Belgium E. Falsen, Swedene
16.11 (ATCC 35317 T1) Human arm wound USA
16.12 (WG-06) Human clinical specimen Germany G. Stempfel, Germanyc
16.13 (WG-07) Human clinical specimen Germany
16.14 (WG-08) Human clinical specimen Germany
16.15 (WG-09) Human clinical specimen Germany
16.16 (WG-10) Human clinical specimen Germany
16.17 (WG-11) Human clinical specimen Germany
16.18 (WG-12) Human clinical specimen Germany
16.19 (WG-13) Human clinical specimen Germany
16.20 (WG-14) Human clinical specimen Germany
16.21 (WG-15) Human clinical specimen Germany
16.22 (WG-16) Human clinical specimen Germany
16.23 (WG-17) Human clinical specimen Germany
16.24 (WG-18) Human clinical specimen Germany
16.25 (CCUG 21195) Environment France E. Falsen, Swedene
16.26 (CCUG 29891) Milk Czech Republic
E. gergoviae (n¼ 28)
14.01 (T780/77) Human clinical specimen Unknown H. Backes, Germanya
14.02 (34/72) Human clinical specimen Unknown
14.03 (87/921/4) Human clinical specimen Unknown
14.04 (T782/7) Human clinical specimen Unknown
14.05 (T694/78) Human clinical specimen Unknown
14.06 (T691/78) Human clinical specimen Unknown
14.07 (T692/78) Human clinical specimen Unknown
14.08 (585-9987) Human clinical specimen Unknown
14.09 (II-8-41) Human clinical specimen Germany Own culture collection
14.10 (Eg1) Human clinical specimen Switzerland A. v. Graevenitz, Switzerlandb
14.11 (Eg2) Human clinical specimen Switzerland
14.12 (ATCC 33028T, CUETM 79-1) Human urinary tract USA E. Falsen, Swedene
14.13 (WG-19) Human clinical specimen Germany G. Stempfelc
14.14 (WG-20) Human clinical specimen Germany
14.15 (WG-21) Human clinical specimen Germany
14.16 (WG-22) Human clinical specimen Germany
14.17 (WG-23) Human clinical specimen Germany
14.18 (WG-24) Human clinical specimen Germany
14.19 (CCUG 29882) Human feces Czech Republic E. Falsen, Swedene
14.20 (CCUG 29883) Human sputum Czech Republic
14.21 (CCUG 29884) Hospital environment Czech Republic
14.22 (CCUG 29885) Human urine Czech Republic
14.23 (CCUG 29886) Hospital environment Czech Republic
14.24 (CCUG 29887) Human sputum Czech Republic
14.25 (CCUG 29888) Human sputum Czech Republic
14.26 (CCUG 29889) Human urine Czech Republic
14.27 (CCUG 29890) Human feces Czech Republic
14.28 (CCUG 33719) Human blood Sweden
E. sakazakii (n¼ 35)
15.03 (T260/74) Human clinical specimen Unknown H. Backes, Germanya
15.04 (899) Human clinical specimen Unknown
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33028T, E. sakazakii ATCC 29544T and Escherichia
coli ATCC 25922 were used as control strains for
susceptibility testing.
Identification
The identification of the strains was confirmed
with a commercial identification system for Ente-
robacteriaceae (Micronaut-E, Merlin-Diagnostika,
Bornheim, Germany). This identification system
contains biochemical key reactions for most clini-
cally significant Enterobacteriaceae species. The
inoculum for the identification tests was a suspen-
sion from an overnight culture on Isosensitest agar
(Oxoid, Basingstoke, UK) in physiological saline
solution at 106 colony-forming units (CFU)/mL;
the incubation times were 24 h at 37 8C.
Antibiotics and antibiotic susceptibility
testing
Antibiotic susceptibility was tested with a micro-
dilution procedure in Isosensitest broth (Oxoid).
Seven strains of each species were also tested in
cation-adjusted Mueller–Hinton broth (CAMHB;
Difco Laboratories, Detroit, MI, USA). After
Table 1 continued
Origin
Strain (additional designation) Material Country Source
15.05 (903) Human clinical specimen Unknown
15.06 (2285-Q5) Human clinical specimen Unknown
15.07 (9529) Human clinical specimen Unknown
15.08 (CCUG 10788) Tin of milk UK
15.10 (ATCC 29544T, LMG 5740) Human throat (child) USA
15.11 (ES02) Human clinical specimen Switzerland A. v. Graevenitz, Switzerlandb
15.12 (ES03) Human clinical specimen Switzerland
15.13 (ES07) Human clinical specimen Switzerland
15.14 (ES08) Human clinical specimen Switzerland
15.15 (ES09) Human clinical specimen Switzerland
15.16 (ES10) Human clinical specimen Switzerland
15.17 (ES11) Human clinical specimen Switzerland
15.18 (ES12) Human clinical specimen Switzerland
15.19 (ES13) Human clinical specimen Switzerland
15.20 (ES14) Human clinical specimen Switzerland
15.21 (WG-25) Human clinical specimen Germany G. Stempfel, Germanyc
15.22 (WG-26) Human clinical specimen Germany
15.23 (WG-27) Human clinical specimen Germany
15.24 (WG-28) Human clinical specimen Germany
15.25 (WG-29) Human clinical specimen Germany
15.26 (WG-30) Human clinical specimen Germany
15.27 (WG-31) Human clinical specimen Germany
15.28 (WG-32) Human clinical specimen Germany
15.29 (WG-33) Human clinical specimen Germany
15.30 (WG-34) Human clinical specimen Germany
15.31 (WG-35) Human clinical specimen Germany
15.32 (WG-36) Human clinical specimen Germany
15.33 (WG-37) Human clinical specimen Germany
15.34 (CUETM 79-14, LMG 2758) Human ear USA J. Swings, Belgiumd
15.35 (CUETM 79-35, LMG 2759) Human throat USA
15.36 (CUETM 79-28, LMG 2760) Hand brush USA
15.37 (CUETM 79-23, LMG 2762) Human blood culture USA
15.38 (CUETM 79-26, LMG 2763) Human finger abscess USA
aMerlin-Diagnostika, Bornheim.
bInstitute of Medical Microbiology, University of Zu¨rich.
cGa¨rtner and Colleagues Laboratory, Weingarten.
dBCCMTM/LMG Bacteria collection, University of Gent.
eDepartment of Clinical Bacteriology, Culture Collection, University of Go¨teborg.
T, Type strain; T1, formerly Type strain of E. taylorae.
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inoculation of antibiotic-containing microtitration
plates (Merlin-Diagnostika) with 100 mL of appro-
priate bacterial suspension (3 105 to 7 105
CFU/mL) and incubation for 22 h at 37 8C, the
minimum inhibitory concentration (MIC) values
were determined with a photometer for microtitre
plates (Labystems Multiscan Multisoft, Helsinki,
Finland). MIC data were evaluated using Excel
(Microsoft). All antibiotics were kindly provided
to Merlin-Diagnostika by their manufacturers.
Evaluation of natural antibiotic susceptibility
Plotting the MIC of a particular antibiotic for one
species against the number of strains found with
the respective MIC usually results in a bimodal
distribution. One peak with relatively low MICs
represents the natural population and one peak
with higher MICs represents the strains with
acquired (secondary) resistance. Analysis of the
MIC distribution of all strains of one species for
each antibiotic permitted the determination of the
biological thresholds, which limit the natural
population at high MICs, but not those strains
with secondary resistance. The MIC values of
the natural population were investigated to deter-
mine whether they were above or below the break-
points of the standards, which assess the clinical
susceptibility. When the natural population was
sensitive or intermediate according to the cited
standard, it was described as naturally sensitive
or naturally intermediate, respectively. When the
natural population was clinically resistant, it was
described as naturally (intrinsically) resistant. The
method has been described in detail previously
[24–26]. Clinical breakpoints for apramycin, livi-
domycin A and ribostamycin were defined as
proposed recently [27].
R E S U L T S
There were no, or only small, species-related
differences in natural susceptibility to most
antimicrobial agents. All the species were natu-
rally sensitive or intermediate to tetracyclines,
aminoglycosides, acylureidopenicillins, ticarcillin,
ampicillin/sulbactam, several cephalosporins,
carbapenems, aztreonam, quinolones, antifolates,
chloramphenicol and nitrofurantoin. Natural
resistance was found to benzylpenicillin, oxacillin,
the macrolides except azithromycin, lincosamides,
streptogramins, glycopeptides, rifampicin and
fusidic acid. Significant differences in natural sus-
ceptibility to someb-lactams were found among the
species, azithromycin and fosfomycin. Whereas
E. gergoviae was the most susceptible species to
azithromycin, E. cancerogenus was most suscepti-
ble to fosfomycin. Twenty-two of the 26 strains of
the latter species were uniformally resistant or
intermediate to amoxicillin, amoxicillin/clavula-
nate, cefaclor, cefazoline, loracarbef and cefoxitin,
showing the natural resistance of E. cancerogenus to
these agents (see Discussion). This was in contrast
to the remaining Enterobacter species tested, which
were naturally sensitive or intermediate to all b-
lactams except benzylpenicillin, oxacillin and
cefoxitin. Apart from E. cancerogenus, E. gergoviae
was the species least susceptible to cefoxitin. Sixty-
four per cent of the strains belonging to the natural
population of E. gergoviae were intermediate or
resistant to this cephalosporin. Although not
resistant to any cephalosporins, E. amnigenus
showed susceptibility patterns similar to that of
E. cancerogenus to some cephalosporins and was
less susceptible than E. gergoviae and E. sakazakii to
loracarbef, cefotiam, cefixim, cefpodoxime, cefdi-
nir and ceftibutene. An overview of the antibiotic
susceptibilities of the tested Enterobacter strains is
shown in Table 2. The natural antibiotic sensitiv-
ities and resistances are summarized in Table 3.
Medium dependency in susceptibility testing
For most of the tested antibiotics, there were no, or
minor, differences in susceptibility, dependent on
the medium. For all the species, the MICs of
tetracyclines were generally two doubling dilution
steps higher in Isosensitest broth than in CAMHB
(data not shown). This led to the absence of strains
of intermediate susceptibility to tetracyclines in
the presence of CAMHB. Medium-dependent
differences in susceptibility were also obtained
for the macrolides tested. The MICs of macrolides
were one to two doubling dilution steps higher
in Isosensitest broth. These differences affected
the clinical assessment of the MICs for the natural
populations of all species for azithromycin
(Table 2).
Quality assurance
In both media the MIC data of all antibiotics were
reproducible for the control strains examined. The
MIC values for E. coli ATCC 25922 in Isosensitest
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Table 2 Antibiotic susceptibility of E. amnigenus, E. cancerogenus, E. gergoviae and E. sakazakiia
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Table 2 continued
aThe number of strains with the corresponding MIC value is cited. Strains in the column for the lowest concentration of the
antibiotic (cmin) have MICs this lowest concentration (MIC¼ cmin! MIC cmin). MICs higher than the highest
concentration tested were assigned to twice the highest concentration which was tested. MIC values in the shaded areas
indicate the clinically intermediate area according to the German standard (DIN). A black thick line indicates the
breakpoint between clinically sensitive and clinically resistant strains, if the ‘intermediate’ does not apply. If the DIN
criteria for an antibiotic are not applicable, other standards were employed. NCCLS breakpoints were used for
spectinomycin, cefdinir, dalfopristin, quinupristin, dalfopristin/quinupristin, sulfamethoxazole and teicoplanin; French
standards were used for streptomycin, kanamycin, neomycin, pefloxacin, lincomycin and fosfomycin and Swedish criteria
were used for roxithromycin, clarithromycin, rifampicin and fusidic acid. UK breakpoints were used for trimethoprim.
Breakpoints for apramycin, ribostamycin and lividomycin A were defined as recently proposed [27].
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Table 3 Natural antibiotic susceptibility (þ) of E. amnigenus, E. cancerogenus, E. gergoviae and E. sakazakii, classified as
sensitive, intermediate and resistant according to the standards mentioned in Table 2
Antibiotic Species
Naturally
sensitive
Naturally
intermediate
Naturally
resistant
Tetracyclinesa All tested tetracyclines All species þ þ
Aminoglycosides All tested aminoglycosides All species þ
Penicillins Benzylpenicillin, Oxacillin All species þ
Amoxicillin E. cancerogenus þ
E. amnigenus, E. gergoviae þ þ
E. sakazakii þ
Amoxicillin/Clavulanate E. cancerogenus þ
E. gergoviae þ þ
E. amnigenus, E. sakazakii þ
Ampicillin/Sulbactam E. cancerogenus þ þ
All species except E. cancerogenus þ
All further tested
penicillins
All species þ
Cephalosporins Cefoxitin E. cancerogenus þ
E. gergoviae þ þ þ
E. amnigenus, E. sakazakii þ þ
Cefaclor E. cancerogenus þ
E. amnigenus þ
E. sakazakii þ þ
E. gergoviae þ
Cefazoline E. cancerogenus þ
All species except
E. cancerogenus
þ
Loracarbef E. cancerogenus þ þ
All species except
E. cancerogenus
þ
Cefuroxime E. cancerogenus, E. gergoviae þ þ
E. amnigenus þ þ
E. amnigenus, E. sakazakii þ
Ceftibutene E. amnigenus þ þ
All species except
E. amnigenus
þ
All further tested
cephalosporins
All species þ
Carbapenems All tested carbapenems All species þ
Monobactams Aztreonam All species þ
Quinolones All tested quinolones All species þ
Macrolidesa All macrolides All species þ
except azithromycin
Azithromycin E. cancerogenus þ
E. sakazakii þ þ
E. amnigenus þ þ þ
E. gergoviae þ þ
Lincosamides Lincomycin, Clindamycin All species þ
Streptogramins All tested streptogramins All species þ
Glycopeptides Teicoplanin, Vancomycin All species þ
Antifolates All tested antifolates All species þ
Other antibiotics Rifampicin All species þ
Fusidic acid All species þ
Fosfomycin All species except
E. cancerogenus
þ
E. cancerogenus þ
Chloramphenicol All species þ
Nitrofurantoin All species þ
aData only valid in the presence of Isosensitest broth (see Results).
Note: If 20% of the strains belonging to a natural population were attributed to one of the clinical categories, these
percentages were disregarded.
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broth and CAMHB were within the control limits
for susceptibility testing according to DIN criteria
(data not shown).
D I S C U S S I O N
In the literature, information on antimicrobial sus-
ceptibilities of recently established Enterobacter
species is usually restricted to a small number of
strains and/or a few antibiotics. In most cases data
on natural sensitivities or resistances only refer to
well-established Enterobacter taxa. The present
study was conducted to establish a database con-
cerning the natural susceptibility to a range of
antibiotics for some ‘new’ Enterobacter species.
These data can be valuable for the validation of
routine antibiotic susceptibility test results and
give insight into the respective mechanisms of
natural resistance.
Natural susceptibility to b-lactams
The most extensive studies published on ‘new’
Enterobacter species were performed by Farmer
et al. [15] and Muytjens et al. [28]. Both studies
included susceptibility data for E. cancerogenus,
which was the least susceptible species to b-lac-
tams in the present study. Our data showing
natural resistance to aminopenicillins and several
‘older’ cephalosporins are in accordance with
Muytjens et al., who found all strains examined
(n¼ 10) to be highly resistant to ampicillin and
cefazolin, applying an agar-dilution procedure
[28]. Farmer et al., however, showed that only
53% of the total population (n¼ 32) were resistant
to ampicillin [15]. These results are not surprising,
in view of the fact that Farmer and co-workers
used an agar-diffusion technique, whose results in
some instances disagree with the results obtained
by dilution procedures [29–31]. In particular, in a
study published recently, it was demonstrated that
there are method-associated dependencies in the
results of susceptibility tests for Enterobacter spe-
cies [30]. Further reports on aminopenicillin-sen-
sitive E. cancerogenus strains were published by
Martinez et al., who found one strain among two
ampicillin-resistant strains to be aminopenicillin
sensitive [17], and by Westblom and Coggins, who
isolated one ampicillin-sensitive strain from a
wound infection [21]. Whereas, in the latter case,
it cannot be excluded that the result was due to the
method applied (which was not stated), there is
evidence that in both cases the result was attrib-
uted to strains with acquired sensitivity, as docu-
mented in the present study according to four of
the strains tested (Table 2). (The phenomenon of
‘acquired sensitivity’ describes a relatively rare
phenotype but it occurs for some antibiotics in
nearly all Enterobacteriaceae species; see ref. [32]
for an overview). The phenotype of E. cancero-
genus, showing natural resistance to amoxicillin
and amoxicillin/clavulanic acid as well as to the
cephalosporin derivatives cefaclor, cefazoline, lor-
acarbef and cefoxitin is similar to the natural b-
lactam phenotypes of well-established Enterobacter
species, and indicates the presence of chromoso-
mally encoded AmpC b-lactamases in this species.
Class C enzymes are responsible for the respective
phenotypes in strains of the E. cloacae complex and
of E. aerogenes [30,33]. In agreement with our
thesis, Pitout et al. recently found inducible AmpC
b-lactamases in all E. cancerogenus strains exam-
ined (n¼ 6) (referred from the authors as Bush
group 1) with isoelectric point (pI) values >9,
indicating enzymes similar to those found in the
same study in wild-type strains of the E. cloacae
complex (pIs 8.0 to>9) and of E. aerogenes (pIs 8.4–
8.8) [30].
Apart from natural resistances to aminopenicil-
lins, amoxicillin/clavulanic acid and narrow-spec-
trum cephalosporins, the intrinsic resistance to
cefoxitin is a common feature of numerous Enter-
obacter species. According to our data, natural
high-level cefoxitin resistance in Enterobacter spe-
cies is present in strains of E. cancerogenus (as
presented here), E. aerogenes, E. cloacae, E. hormae-
chei and E. asburiae (unpublished data). It is of
particular interest that in this study the majority
of the strains of the natural population of E. ger-
goviae were resistant or intermediate to cefoxitin
(Table 2). This indicates that E. gergoviae—which
was sensitive or intermediate to amoxicillin and to
all remaining cephalosporins tested (Tables 2 and
3)—expresses a distinct naturally occurring b-lac-
tamase at low levels and that the enzyme assumed
shows a more or less specific ‘cefoxitinase’ activity.
Recently, a low-level activity of a not-inducible
AmpC-b-lactamase was demonstrated in three E.
gergoviae strains [30].
As for E. cancerogenus and E. gergoviae, chromo-
somally encoded b-lactamases have to be postu-
lated for E. amnigenus strains. Although there was
no natural resistance to cephalosporins, including
cefoxitin, a decreased susceptibility was found to
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 564–578
Stock and Wiedemann Natural antibiotic susceptibility of recently established Enterobacter spp. 575
cefixime, cefpodoxime and ceftibutene, compared
to the natural populations of E. gergoviae and E.
sakazakii (Table 2). This species-associated pheno-
type indicates the presence of at least one naturally
occurring enzyme, expressed at low levels. b-Lac-
tamase studies have not been published for strains
of E. amnigenus.
In contrast to the species mentioned above, the
susceptibility testing of natural populations of E.
sakazakii to b-lactams gave no evidence for the
expression of any b-lactamases. In agreement with
the data of Muytjens and van de Ros-van de Repe
[28], the data of this study show that E. sakazakii
is the Enterobacter species most susceptible to b-
lactam antibiotics examined so far. Reports indica-
ting a naturally occurring high susceptibility of E.
sakazakii to numerous b-lactams have appeared
repeatedly, but in all but two studies [1,28] only
a few strains were included. However, the absence
of b-lactamases in E. sakazakii was refuted in a
recent study by Pitout et al. [30]. It was shown
that E. sakazakii strains sensitive to all cephalos-
porins including cefoxitin produced Bush group 1
b-lactamases with pIs of 7.4–8.0 at low levels.
Enterobacteriaceae species which naturally express
their b-lactamases at negligible or low levels are
not uncommon and include several species, e.g.
Escherichia coli and Shigella spp. [34], Proteus
mirabilis [35] and Edwardsiella tarda [36]. In general,
b-lactam MICs for these species do not signifi-
cantly differ from the MICs seen for some b-lac-
tamase-negative Enterobacteriaceae. In the case of
E. sakazakii, the MIC values of b-lactams were
nearly identical to the b-lactam MICs seen for
the natural populations of Salmonella enterica
[37], which is known to produce no naturally
occurring b-lactamase [35].
Natural susceptibility to other antibiotics
The natural resistance of all species to rifampicin,
lincosamides, glycopeptides, streptogramins and
fusidic acid was expected, since resistance to these
agents is a typical feature of nearly all Enterobac-
teriaceae and has been largely attributed to the
outer membrane of these bacteria, which repre-
sents a more or less strong barrier to these agents
[38]. Significant differences in susceptibility to
non-b-lactams, leading to different categorizations
by the standards applied, were only found for
fosfomycin and azithromycin (Tables 2 and 3).
The molecular background of the species-related
differences in fosfomycin susceptibility is not
understood and awaits further study. Because
there was no naturally occurring high-level fosfo-
mycin resistance in E. amnigenus and E. gergoviae, it
is likely that a reduced permeability of the cell
membrane in the presence of this antibiotic, rather
than a specific fosfomycin:gluthathione-S-transfer-
ase, contributed to the phenotype observed
(Table 2). Alternatively, a transferase with low
affinity to fosfomycin or a low-level enzyme
expression would be possible [39]. It should be
noted that results in fosfomycin susceptibility test-
ing are highly dependent on the constituents of the
media and on several further factors [40]. How-
ever, according to the data there were no differ-
ences in fosfomycin susceptibility dependent on
the medium (data not shown). The natural resis-
tance of Enterobacter species to the macrolides,
excepting azithromycin is probably due to the
barrier function of the outer membrane [38]. The
higher susceptibility of the species tested to azi-
thromycin—resulting in some clinically sensitive
E. gergoviae strains—was not unexpected since
azithromycin diffuses significantly better than
other macrolides through several porin channels,
and is known to interact with the acidic lipopoly-
saccharide, penetrating the outer membrane by
virtue of this interaction (see [41] for an overview).
Species-dependent differences in macrolide sus-
ceptibility might be due to variations of the mem-
brane architecture resulting in a cell envelope with
species-specific hydrophobicity.
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